Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Roflumilast for COPD exacerbation reduction (REACT)
NCT01329029Phase 4Completed
- Sponsor
- AstraZeneca
- Start
- May 2011
- Primary completion
- Mar 2014
- Modality
- Small Molecules
- Countries
- 21
01
Overview
A Phase 4 trial of roflumilast in chronic obstructive pulmonary disease (COPD), sponsored by AstraZeneca. Started May 2011; status: completed.
02
Drugs
roflumilast
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT01329029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01329029.